GGrantIndex
← Leaderboards

Matthew Aaron Ciorba

Washington University

$5,955,912
Attributed
$8,250,051
Total exposure
10
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.9M · FY201025
$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,250,051 · 10

By mechanism

R01$5,999,854 · 3
K08$712,401 · 1
T32$506,446 · 1
R21$364,856 · 1
R56$304,049 · 1
P30$160,445 · 1

Top collaborators

Most similar at Washington University

Same institution · by research overlap

Others in their field

Top investigators on “Intestines

Research focus

IntestinesPathway InteractionsEpithelial CellsInflammatory Bowel DiseasesLeadChronicMalignant NeoplasmsCellsColitisSamplingResponseColonOrganoidsEpithelialAffectBiobankEpitheliumGrowthInnovationTumorSiteGastrointestinal Tract StructureImmuneFunctional Disorder

Grant awards (25)

Targeting Tryptophan Metabolism in Rectal Cancer$633,826
R01 · FY2025 · CA · contact PI
Mechanisms of Gastrointestinal COVID-19$588,062
R01 · FY2025 · AI · contact PI
Clinical/Laboratory Training Academic Gastroenterology$506,446
T32 · FY2025 · DK · contact PI
Organoids and Gene Editing Core$160,445
P30 · FY2025 · DK · contact PI
GI Epithelium: Interface with the Outside World$50,000
R13 · FY2025 · DK · contact PI
Targeting Tryptophan Metabolism in Rectal Cancer$633,106
R01 · FY2024 · CA · contact PI
Mechanisms of Gastrointestinal COVID-19$625,575
R01 · FY2024 · AI · contact PI
Mechanisms of Gastrointestinal COVID-19$705,849
R01 · FY2023 · AI · contact PI
Targeting Tryptophan Metabolism in Rectal Cancer$513,828
R01 · FY2023 · CA · contact PI
Mechanisms of Gastrointestinal COVID-19$583,983
R01 · FY2022 · AI · contact PI
Mechanisms of Gastrointestinal COVID-19$304,049
R56 · FY2022 · AI · contact PI
TARGETING TRYPTOPHAN METABOLISM IN COLITIS ASSOCIATED CANCER$343,125
R01 · FY2020 · DK · contact PI
TARGETING TRYPTOPHAN METABOLISM IN COLITIS ASSOCIATED CANCER$343,125
R01 · FY2019 · DK · contact PI
TARGETING TRYPTOPHAN METABOLISM IN COLITIS ASSOCIATED CANCER$343,125
R01 · FY2018 · DK · contact PI
TARGETING TRYPTOPHAN METABOLISM IN COLITIS ASSOCIATED CANCER$343,125
R01 · FY2017 · DK · contact PI
PROBIOTICS TO PREVENT GI SIDE EFFECTS FROM CHEMORADIATION FOR ABDOMINAL MALIGNANCY$132,675
R21 · FY2017 · CA · contact PI
TARGETING TRYPTOPHAN METABOLISM IN COLITIS ASSOCIATED CANCER$343,125
R01 · FY2016 · DK · contact PI
PROBIOTICS TO PREVENT GI SIDE EFFECTS FROM CHEMORADIATION FOR ABDOMINAL MALIGNANCY$232,181
R21 · FY2016 · CA · contact PI
IDO1 IN THE HUMAN GUT EPITHELIUM$76,000
R03 · FY2015 · DK · contact PI
Indoleamine 2,3 Dioxygenase in Colitis Associated Cancer$141,795
K08 · FY2014 · DK · contact PI
IDO1 IN THE HUMAN GUT EPITHELIUM$76,000
R03 · FY2014 · DK · contact PI
Indoleamine 2,3 Dioxygenase in Colitis Associated Cancer$142,147
K08 · FY2013 · DK · contact PI
Indoleamine 2,3 Dioxygenase in Colitis Associated Cancer$142,509
K08 · FY2012 · DK · contact PI
Indoleamine 2,3 Dioxygenase in Colitis Associated Cancer$142,906
K08 · FY2011 · DK · contact PI
Indoleamine 2,3 Dioxygenase in Colitis Associated Cancer$143,044
K08 · FY2010 · DK · contact PI